Our technology reveals, besides known signaling pathway activation, T-loop phosphorylations of the elusive RIPK1 S161, dynamic activation of primary blood platelets, rewiring of signal transduction in melanoma upon acquired drug resistance, and global kinase activity status in a breast cancer tumor biopsy sample. This evidence concerns the gene RIPK1 and breast carcinoma.